Advanced glycation endproducts: Production and pathophysiological significance;Produits de glycation avancée: Production et signification physiopathologique

Cahiers de Nutrition et de Dietetique

Volumn 38, Issue 2, 2003, Pages 122-129

  Bonnefont Rousselot, Dominique ^a,b  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Advanced glycation end product; AGE; Diabetes; Glycation; RAGE; Receptor for advanced glycation end products; Treatment

Indexed keywords

ADVANCED GLYCATION END PRODUCT; AMINOGUANIDINE; ANTIDIABETIC AGENT; CYTOKINE; ENDOTHELIN 1; GLUCOSE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1ALPHA; INTERLEUKIN 6; METFORMIN; MITOGEN ACTIVATED PROTEIN KINASE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE INHIBITOR; ORAL ANTIDIABETIC AGENT; RECEPTOR FOR ADVANCED GLYCATION END PRODUCT; RECOMBINANT GLYCATION END PRODUCT RECEPTOR; THROMBOMODULIN; THROMBOPLASTIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ANTIOXIDANT ACTIVITY; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; DIABETES MELLITUS; DIABETIC NEPHROPATHY; GLUCOSE BLOOD LEVEL; GLYCATION; HUMAN; HYPERGLYCEMIA; INFLAMMATION; KIDNEY DISEASE; LIPID PEROXIDATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; REVIEW; VASCULAR ENDOTHELIUM;

EID: 0037665187     PISSN: 00079960     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (78)

1. Stern D.M., Yan S.D., Yan S.F., Schmidt A.M. - Receptor for advanced glycation endproducts (RAGE) and the complications of diabetes. Ageing Res. Rev., 2002, 1, 1-15.
2. Maillard L.C. - Condensation des acides aminés sur les sucres; formation de mélanoïdines par voie méthodique. C.R. Acad. Sci. Paris, 1912, 154, 66-8.
3. Singh R., Barden A., Mori T., Beilin L. - Advanced glycation endproducts: a review. Diabetologia, 2001, 44, 129-46.
4. Gillery P., Dumont G., Vassault A. - Evaluation of glycohemoglobin assays in France by national quality control surveys. Diabetes Care, 1998, 21, 265-70.
5. Armbruster D.A. - Fructosamine: structure, analysis and clinical usefulness. Clin. Chem., 1987, 33, 2157-63.
6. Gugliucci A. - Glycation as the glucose link to diabetic complications. J. Am. Osteopath. Assoc., 2000, 100, 621-34.
7. Traverso N., Menini S., Cottalasso D., Odetti P., Marinari U.M., Pronzato M.A. - Mutual interaction between glycation and oxidation during non-enzymatic protein modification. Biochim. Biophys. Acta, 1997, 1336, 409-18.
8. Thornalley P.J., Langborg A., Minhas H.S. - Formation of glyoxal, methylglyoxal and 3-DG in the glycation of proteins. Biochem. J., 1999, 344, 109-16.
9. Nicholl I.D., Bucala R. - AGE and cigarette smoking. Cell Mol. Biol., 1998, 44, 1025-33.
10. O'Brien J., Morrissey P.A. - Nutritional and toxicological aspects of the Maillard browning reaction in foods. Crit. Rev. Food Sci. Nutr., 1989, 28, 211-48.
11. Koschinsky T., He C.J., Mitsuhashi T. et al. - Orally absorbed reactive glycation products (glycotoxins): an environmental risk factor in diabetic nephropathy. Proc. Natl. Acad. Sci. USA, 1997, 94, 6474-79.
12. Gillery P., Monboisse J.C., Macquart F.X., Borel J.P. Glycation of proteins as a source of superoxide. Diabetes Metab., 1998, 14, 25-30.
13. Hunt J.V., Dean R.T., Wolff S.P. - Hydroxyl radical production and autoxidative glycosylation. Glucose autoxidation as the cause of protein damage in the experimental glycation model of diabetes mellitus and aging. Biochem. J., 1988, 15, 205-12.
14. Bonnefont-Rousselot D. - Glucose and reactive oxygen species. Curr. Opin. Clin. Nutr. Metab. Care, 2002, 5, 561-8.
15. Baynes J., Thorpe S. - Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. Diabetes, 1999, 48, 1-9.
16. Miyata T., Sugiyama S., Saito A., Kurokawa K. - Reactive carbonyl compounds-related uremic toxicity (« carbonyl stress »). Kidney Int., 2001, 59, S25-S31.
17. Makita Z., Radoff S., Rayfield E.J. et al. - Advanced glycosylation endproducts in patients with diabetic nephropathy. N. Engl. J. Med., 1991, 325, 836-42.
18. Monnier V.M., Kohn R.R., Cerami A. - Accelerated agerelated browning of human collagen in diabetes mellitus. Proc. Natl. Acad. Sci. USA, 1984, 81, 583-9.
19. Verzijl N., DeGroot J., Ben Z.C. et al. - Crosslinking by advanced glycation end products increases the stiffness of the collagen network in human articular cartilage: possible mechanism through which age is a risk factor for osteoarthritis. Arthritis Rheum., 2002, 46, 114-23.
20. Brownlee M., Vlassara H., Cerami A. - Nonenzymatic glycosylation products on collagen covalently trap lowdensity lipoprotein. Diabetes, 1983, 34, 938-41.
21. Makino H., Shikata K., Hironaka K. et al. - Ultrastructure of nonenzymatically glycated mesangial matrix in diabetic nephropathy. Kidney Int., 1995, 48, 517-26.
22. Matsumoto K., Ikeda K., Horiuchi S., Zhao H., Abraham E.C. - Immunochemical evidence for increased formation of advanced glycation end products and inhibition by aminoguanidine in diabetic rat lenses. Biochem. Biophys. Res. Commun., 1997, 241, 352-4.
23. Stitt A.W., Moore J., Sharkey J.A. et al. - Advanced glycation endproducts in vitreous: structural and functional implications for diabetic vitreopathy. Invest. Ophtalmol. Vis. Sci., 1998, 39, 2517-23.
24. Bucala R., Mitchell R., Arnold K., Innerarity T., Vlassara, Cerami A. - Identification of the major site of apolipoprotein B modification by advanced glycosylation endproducts blocking uptake by the low density lipoprotein receptor. J. Biol. Chem., 1995, 270, 10828-32.
25. Bucala R., Makita Z., Koschinsky T., Cerami A., Vlassara H. - Lipid advanced glycosylation: pathway for lipid oxidation in vivo. Proc. Natl. Acad. Sci. USA, 1993, 90, 6434-38.
26. Stitt A.W., He C., Friedman S. et al. - Elevated AGE-modified apo B in the sera of euglycemic, normolipidemic patients with atherosclerosis. Mol. Med., 1997, 3, 61727.
27. Bucala R., Model P., Cerami A. - Modification of DNA by reducing sugars: a possible mechanism for nucleic acid aging and age-related dysfunction in gene expression. Proc. Natl. Acad. Sci. USA, 1984, 81, 105-9.
28. Mills J.L., Baker L., Goldman A.S. - Malformations in infants of diabetic mothers occur before the seventh gestational week. Implications for treatment. Diabetes, 1979, 28, 292-3.
29. Vlassara H., Palace M.R. - Diabetes and advanced glycation endproducts. J. Intern. Med., 2002, 251, 87-101.
30. Schmidt A.M., Hofmann M., Taguchi A., Yan S.D., Stern D.M. - RAGE: a multiligand receptor contributing to the cellular response in diabetic vasculopathy and inflammation. Semin. Thromb. Hemost., 2000, 26, 485-93.
31. Thornalley P.J. - Cell activation by glycated proteins. AGE receptors, receptor recognition factors and functional classification of AGEs. Cell Mol. Biol., 1998, 44, 1013-23.
32. Neeper M., Schmidt A.M., Brett J. et al. - Cloning and expression of a cell surface receptor for advanced glycosylation endproducts of proteins. J. Biol. Chem., 1992, 267, 14998-5004.
33. ε-(carboxymethyl)lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signalling pathways and modulate gene expression. J. Biol. Chem., 1999, 274, 31740-9.
34. ras-dependent mitogen-activated protein kinase pathway regulated by oxidant stress. J. Biol. Chem., 1997, 272, 17810-4.
35. Yan S.D., Schmidt A.M., Anderson G.M. et al. - Enhanced cellular oxidant stress by the interaction of advanced glycation end-products with their receptors-binding proteins. J. Biol. Chem., 1994, 269, 9889-97.
36. Heidland A., Sebekova K., Schinzel R. - Advanced glycation end products and the progressive course of renal disease. Am. J. Kidney Dis., 2001, 38, S100-S106.
37. Schmidt A.M., Hori O., Chen J.X. et al. - Advanced glycation endproducts interacting with their endothelial receptor induce expression of VCAM-1 in cultured human endothelial cells and in mice. J. Clin. Invest. 1995, 96, 1395-403.
38. Biehraus A., Hofmann M.A., Ziegler R., Nawroth P.P. - AGE and their interactions with AGE receptors in vascular disease and diabetes. I. The AGE concept. Cardiovasc. Res., 1998, 37, 586-600.
39. Hudson B.I., Stickland M.H., Grant P.J. - Identification of polymorphisms in the receptor for advanced glycation end products (RAGE) gene: prevalence in type 2 diabetes and ethnic groups. Diabetes, 1998, 47, 1155-7.
40. Kañkova K., Záhejský J., Márová I. et al. - Polymorphisms in the RAGE gene influence susceptibility to diabetes-associated microvascular dermatoses in NIDDM. J. Diabetes Complications, 2001, 15, 185-92.
41. Kañkova K., Márová I., Záhejský J. et al. - Polymorphisms 1704G/T and 2184A/G in the RAGE gene are associated with antioxidant status. Metabolism, 2001, 50, 1152-60.
42. Hofmann M.A., Drury S., Fu C. et al. - RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100-calgranulin polypeptides. Cell, 1999, 97, 889-901.
43. Schmidt A.M., Yan S.D., Wautier J.L., Stern D. - Activation of receptors for advanced glycation end products. Circ. Res., 1999, 84, 489-97.
44. Nakamura N., Obayashi H., Fujii M. et al. - Induction of aldose reductase in cultured human microvascular endothelial cells by advanced glycation end products. Free Radic. Biol. Med., 2000, 29, 17-25.
45. Yabe-Nishimura C. - Aldose reductase in glucose toxicity: a potential target for the prevention of diabetic complications. Pharmacol. Rev., 1998, 50, 21-33.
46. Bucala R., Tracey K.J., Cerami A. - Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilation in experimental diabetes. J. Clin. Invest., 1991, 87, 432-8.
47. Teuscher A., Egger M., Hermann J.B. - Diabetes and nephropathy: blood pressure in clinical diabetic patients and control population. Arch. Int. Med., 1989, 149, 1942-5.
48. Honing M.L., Morrison P.J., Banga J.D., Stroes E.S., Rabelink T.J. - Nitric oxide availability in diabetes mellitus. Diabetes Metab. Rev., 1998, 14, 241-9.
49. Zou M.-H., Shi C., Cohen R.A. - Oxidation of the zincthiolate complex and uncoupling of endothelial nitric oxide synthase by peroxynitrite. J. Clin. Invest., 2002, 109, 817-26.
50. Lin K.Y., Ito A., Asagami T. et al. - Impaired nitric oxide synthase pathway in diabetes mellitus. Role of asymmetric dimethylarginine and dimethylarginine dimethylaminohydrolase. Circulation, 2002, 106, 987-92.
51. Stitt A.W., Burke G.A., Chen F., McMullen C.B.T., Vlassara H. - Advanced glycation end-product receptor interactions on microvascular cells occur within caveolin-rich membrane domains. FASEB J., 2000, 14, 2390-2.
52. Bonnefont-Rousselot D. - Thérapeutiques anti-oxydantes et anti-AGE: bilans et perspectives. J. Soc. Biol., 2001, 195, 391-8.
53. Khalifah R.G., Baynes J.W., Hudson B.G. - Amadorins: novel post-Amadori inhibitors of advanced glycation reactions. Biochem. Biophys. Res. Commun., 1999, 257, 251-8.
54. Bucala R., Vlassara H. - Advanced glycosylation endproducts in diabetic renal disease: clinical measurement, pathophysiological significance, and prospects for pharmacological inhibition. Blood Purif., 1995, 13, 160-170.
55. Giardino I., Fard A.K., Hatchell D.L., Brownlee M. - Aminoguanidine inhibits reactive oxygen species formation, lipid peroxidation and oxidant-induced apoptosis. Diabetes, 1998, 47, 1114-20.
56. Edelstein D., Brownlee M. - Mechanistic studies of advanced glycosylation end product inhibition by aminoguanidine. Diabetes, 1992, 41, 26-9.
57. He C., Sabol J., Mitsuhashi T., Vlassara H. - Dietary glycotoxins: inhibition of reactive products by aminoguanidine facilitates renal clearance and reduces tissue sequestration. Diabetes, 1999, 48, 1308-15.
58. Friedman E.A. - Advanced glycosylated end products and hyperglycemia in the pathogenesis of diabetic complications. Diabetes Care, 1999, 22, B65-B71.
59. Freedman B.I., Wuerth J.P., Cartwright K. et al. - Design and baseline characteristics for the aminoguanidine Clinical Trial in Overt Type 2 Diabetic Nephropathy (ACTION II). Control Clin. Trials, 1999, 20, 493-510.
60. Raskin P., Caltran D., William M. et al. - Pimagedine reduces progression of retinopathy and lowers lipid concentrations in patients with Type I diabetes. J. Am. Soc. Nephrol., 1999, 10, 184A (abstract).
61. Appel G., Bolton K., Freedman B. et al. - Pimagedine lowers total urinary protein and slows progression of overt diabetic nephropathy in patients with type I diabetes. J. Am. Soc. Nephrol., 1999, 10, 153A (abstract).
62. Kihara M., Schmelzer J.D., Poduslo J.F., Curran G.L., Nicklander K.K., Low P.A. - Aminoguanidine effects on nerve blood flow, vascular permeability, electrophysiology, and oxygen free radicals. Proc. Natl. Acad. Sci. USA, 1991, 88, 6107-11.
63. Hinson J.A., Bucci T.J., Irwin L.K., Michael S.L., Mayeux P.R. - Effect of inhibitors of nitric oxide synthase on acetaminophen-induced hepatotoxicity in mice. Nitric Oxide, 2002, 6, 160-7.
64. Wiernsperger N.F. - Metformin: intrinsic vasculoprotective properties. Diabetes Technol. Therap., 2000, 2, 259-72.
65. UK Prospective Diabetes Study (UKPDS) Group. - Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes. Lancet, 1998, 352, 854-65.
66. Faure P., Rossini E., Wiernsperger N., Richard M.J., Favier A., Halimi S. - An insulin sensitizer improves the free radical defense system potential and insulin sensitivity in high fructose-fed rats. Diabetes, 1999, 48, 353-7.
67. Bonnefont-Rousselot D., Raji B., Walrand S. et al. - An intracellular modulation of free radical production could contribute to the beneficial effects of metformin towards oxidative stress. Metabolism (sous presse).
68. Ruggiero-Lopez D., Lecomte M., Moinet G., Patereau G., Lagarde M., Wiernsperger N. - Reaction of metformin with dicarbonyl compounds. Possible implication in the inhibition of advanced glycation end product formation. Biochem. Pharmacol., 1999, 58, 1765-73.
69. Pavlovic D., Kocic R., Kocic G. et al. - Effect of fourweek metformin treatment on plasma and erythrocyte antioxidative defense enzymes in newly diagnosed obese patients with type 2 diabetes. Diabetes Obes Metab., 2000, 2, 251-6.
70. Vasan S., Foiles P.G., Founds H.W. - Therapeutic potential of AGE inhibitors and breakers on AGE protein crosslinks. Expert Opin. Invest. Drugs, 2001, 10, 1977-87.
71. Kass D.A., Shapiro E.P., Kawaguchi M. et al. - Improved arterial compliance by a novel advanced glycation end product crosslink breaker. Circulation, 2001, 104, 1464-70.
72. Renard C., Chappey O., Wautier M.P. et al. - Recombinant advanced glycation endproduct receptor pharmacokinetics in normal and diabetic rats. Mol. Pharmacol., 1997, 52, 54-62.
73. Wautier J., Zoukourian C., Chappey O. et al. - Receptormediated endothelial cell dysfunction in diabetic vasculopathy. Soluble receptor for advanced glycation end products blocks hyperpermeability in diabetic rats. J. Clin. Invest., 1996, 97, 238-43.
74. Schmidt A.M., Stern D.M. - RAGE: a new target for the prevention and treatment of the vascular and inflammatory complications of diabetes. Trends Endocrinol. Metab., 2000, 11, 368-75.
75. Schmidt A.M., Stern D.M. - Atherosclerosis and diabetes: the RAGE connection. Curr. Atheroscler. Rep., 2000, 2, 430-6.
76. Park K.L., Ramaw K.G., Lee K.J. et al. - Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycated end-products. Nat. Med., 1998, 4, 1025-31.
77. Clements R.S. Jr., Robinson W.G. Jr., Cohen M.P. Anti-glycated albumin therapy ameliorates early retinal microvascular pathology in db/db mice. J. Diabetes Comp., 1998, 12, 28-33.
78. Nishikawa T., Edelstein D., Du X.L. et al. - Normalising mitochondrial superoxide production blocks three pathways of hyperglycaemia induced damage. Nature, 2000, 404, 787-9.